Enterprise Value

30.25M

Cash

5.843M

Avg Qtr Burn

-10.1M

Short % of Float

4.87%

Insider Ownership

2.82%

Institutional Own.

20.36%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
SLS-005 (trehalose) Details
Spinocerebellar Ataxia

Phase 2/3

Data readout

SLS-005 (trehalose) Details
Amyotrophic lateral sclerosis

Phase 2/3

Data readout

SLS-005 (trehalose) Details
Sanfilippo Syndrome

Phase 2/3

Initiation

SLS-002 (intranasal ketamine) Details
Major depressive disorder, Acute Suicidal Ideation and Behavior

Phase 2

Update

GFH009 Details
Relapsed/refractory acute myeloid leukemia, Acute myeloid leukemia

Phase 1

Data readout

SLS-005 (trehalose) Details
Oculopharyngeal Muscular Dystrophy

Failed

Discontinued

SLS-006 Details
Parkinson's disease

Failed

Discontinued